Monthly CAM2029 Maintains Stable and Extended Acromegaly Control CAM2029 maintained biochemical and symptom control in acromegaly across a 4-week dosing interval, including delays beyond 28 days.

#CAM2029 maintained stable biochemical and symptom control throughout a 4-week dosing interval in patients with #Acromegaly, including among those whose assessments occurred more than 28 days after dosing.

Learn more: https://bit.ly/46zeUp9

#RareDisease #MedSky

FDA Accepts NDA Resubmission for CAM2029 for Patients With Acromegaly The FDA has accepted a resubmitted NDA for CAM2029, a long-acting subcutaneous octreotide formulation for the treatment of acromegaly.

The @fda.gov has accepted a resubmitted New Drug Application (#NDA) for #CAM2029 (Oclaiz™), a long-acting subcutaneous octreotide formulation for the treatment of #Acromegaly, according to a news release from Camurus.

Read more: https://bit.ly/45YO9tJ

#RareDisease #MedSky #Oclaiz

Camurus' POSITANO Study Reveals Promising Results for CAM2029 in Treating Polycystic Liver Disease Camurus' innovative product CAM2029 shows significant efficacy in treating patients with polycystic liver disease as demonstrated in the recent POSITANO study.

Camurus' POSITANO Study Reveals Promising Results for CAM2029 in Treating Polycystic Liver Disease #Sweden #Lund #Camurus #CAM2029 #Polycystic_Liver_Disease

Camurus' POSITANO Study Reveals Promising Effects of CAM2029 for Patients with Polycystic Liver Disease Camurus has unveiled positive results from its POSITANO study, demonstrating that CAM2029 effectively reduces liver volume growth in patients suffering from polycystic liver disease, with an ongoing follow-up planned.

Camurus' POSITANO Study Reveals Promising Effects of CAM2029 for Patients with Polycystic Liver Disease #USA #Lund #Camurus #CAM2029 #Polycystic_Liver_Disease